НовостиBenzingaJP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70 JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70 Benzinga 2026.10.15 13:14 (GMT+0) Открыть на Benzinga Другие новости